Stéphane Fourcade
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Stéphane Fourcade has a total of 266 co-authors. Here are the top co-authors by number of shared publications:
- Aurora Pujol
Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
34 shared publications Montserrat Ruiz
Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, Barcelona, Spain
18 shared publications- Agatha Schlüter
Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
12 shared publications Isidre Ferrer
Department of Pathology and Experimental Therapeutics, Faculty of Medicine, University of Barcelona, L'Hospitalet de Llobregat Barcelona, Spain
12 shared publications- Reinald Pamplona
Department of Experimental Medicine, University of Lleida-Biomedical Research Institute of Lleida (UdL-IRBLleida), Lleida, Spain
11 shared publications - Nathalie Launay
Neurometabolic Diseases Laboratory, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), Hospital Duran i Reynals, L’Hospitalet de Llobregat, Barcelona, Spain
8 shared publications
Latest Publications
- Open Access
Gut microbiota dysbiosis in adrenoleukodystrophy: a new piece in the puzzle?
X-linked adrenoleukodystrophy (X-ALD) is the most common monogenic disorder affecting brain white matter, presenting a broad clinical spectrum from slowly progressive adrenomyeloneuropathy (AMN) to rapidly advancing cerebral demyelination. Factors influencing the variable disease expressivity remain poorly understood. We conducted shotgun metagenomic profiling of fecal samples from X-ALD patients and integrated these data with targeted plasma metabolomic analyses of amino acids and key metabolic intermediates. We identified distinct microbiome-associated metabolic signatures across X-ALD phenotypes. Notably, Bacteroides cellulosilyticus and Helicobacter apodemus abundance were significantly altered in AMN compared with childhood CALD patients. In parallel, X-ALD patients exhibited evidence of microbial metabolic remodeling characterized by altered amino acid metabolism, reduced folate biosynthetic potential, and enrichment of stress-adaptive pathways, including redox-associated functions, glyoxylate shunt activity, lipid A modification, lipopolysaccharide assembly, biofilm adhesin biosynthesis, and curli fiber production. Consistent with these microbial changes, plasma levels of branched-chain amino acids and methionine, as well as serum folate concentrations, were significantly reduced. Importantly, methionine levels showed an inverse correlation with neurofilament light chain (NfL) concentrations in patients with cerebral disease. Our findings reveal a previously unrecognized link between gut microbial metabolic capacity and systemic metabolic alterations in X-ALD. Our results reinforce previous evidence implicating methionine metabolism in disease severity. Collectively, these data support a modulatory role of the microbiota–gut–brain axis in neuroinflammatory and mitochondrial-related processes underlying X-ALD progression and highlight new opportunities for biomarker development and microbiome-informed therapeutic interventions.
Open AccessGut microbiota dysbiosis in adrenoleukodystrophy: a new piece in the puzzle?
X-linked adrenoleukodystrophy (X-ALD) is the most common monogenic disorder affecting brain white matter, presenting a broad clinical spectrum from slowly progressive adrenomyeloneuropathy (AMN) to rapidly advancing cerebral demyelination. Factors influencing the variable disease expressivity remain poorly understood. We conducted shotgun metagenomic profiling of fecal samples from X-ALD patients and integrated these data with targeted plasma metabolomic analyses of amino acids and key metabolic intermediates. We identified distinct microbiome-associated metabolic signatures across X-ALD phenotypes. Notably, Bacteroides cellulosilyticus and Helicobacter apodemus abundance were significantly altered in AMN compared with childhood CALD patients. In parallel, X-ALD patients exhibited evidence of microbial metabolic remodeling characterized by altered amino acid metabolism, reduced folate biosynthetic potential, and enrichment of stress-adaptive pathways, including redox-associated functions, glyoxylate shunt activity, lipid A modification, lipopolysaccharide assembly, biofilm adhesin biosynthesis, and curli fiber production. Consistent with these microbial changes, plasma levels of branched-chain amino acids and methionine, as well as serum folate concentrations, were significantly reduced. Importantly, methionine levels showed an inverse correlation with neurofilament light chain (NfL) concentrations in patients with cerebral disease. Our findings reveal a previously unrecognized link between gut microbial metabolic capacity and systemic metabolic alterations in X-ALD. Our results reinforce previous evidence implicating methionine metabolism in disease severity. Collectively, these data support a modulatory role of the microbiota–gut–brain axis in neuroinflammatory and mitochondrial-related processes underlying X-ALD progression and highlight new opportunities for biomarker development and microbiome-informed therapeutic interventions.
- Open Access
- 15 May 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (10)
Sphingolipid desaturase DEGS1 is essential for mitochondria-associated membrane integrity
Sphingolipids function as membrane constituents and signaling molecules, with crucial roles in human diseases, from neurodevelopmental disorders to cancer, best exemplified in the inborn errors of sphingolipid metabolism in lysosomes. The dihydroceramide desaturase Δ4-dihydroceramide desaturase 1 (DEGS1) acts in the last step of a sector of the sphingolipid pathway, de novo ceramide biosynthesis. Defects in DEGS1 cause the recently described hypomyelinating leukodystrophy-18 (HLD18) (OMIM #618404). Here, we reveal that DEGS1 is a mitochondria-associated endoplasmic reticulum membrane–resident (MAM-resident) enzyme, refining previous reports locating DEGS1 at the endoplasmic reticulum only. Using patient fibroblasts, multiomics, and enzymatic assays, we show that DEGS1 deficiency disrupts the main core functions of the MAM: (a) mitochondrial dynamics, with a hyperfused mitochondrial network associated with decreased activation of dynamin-related protein 1; (b) cholesterol metabolism, with impaired sterol O-acyltransferase activity and decreased cholesteryl esters; (c) phospholipid metabolism, with increased phosphatidic acid and phosphatidylserine and decreased phosphatidylethanolamine; and (d) biogenesis of lipid droplets, with increased size and numbers. Moreover, we detected increased mitochondrial superoxide species production in fibroblasts and mitochondrial respiration impairment in patient muscle biopsy tissues. Our findings shed light on the pathophysiology of HLD18 and broaden our understanding of the role of sphingolipid metabolism in MAM function.
- 15 May 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (10)
Open AccessSphingolipid desaturase DEGS1 is essential for mitochondria-associated membrane integrity
Sphingolipids function as membrane constituents and signaling molecules, with crucial roles in human diseases, from neurodevelopmental disorders to cancer, best exemplified in the inborn errors of sphingolipid metabolism in lysosomes. The dihydroceramide desaturase Δ4-dihydroceramide desaturase 1 (DEGS1) acts in the last step of a sector of the sphingolipid pathway, de novo ceramide biosynthesis. Defects in DEGS1 cause the recently described hypomyelinating leukodystrophy-18 (HLD18) (OMIM #618404). Here, we reveal that DEGS1 is a mitochondria-associated endoplasmic reticulum membrane–resident (MAM-resident) enzyme, refining previous reports locating DEGS1 at the endoplasmic reticulum only. Using patient fibroblasts, multiomics, and enzymatic assays, we show that DEGS1 deficiency disrupts the main core functions of the MAM: (a) mitochondrial dynamics, with a hyperfused mitochondrial network associated with decreased activation of dynamin-related protein 1; (b) cholesterol metabolism, with impaired sterol O-acyltransferase activity and decreased cholesteryl esters; (c) phospholipid metabolism, with increased phosphatidic acid and phosphatidylserine and decreased phosphatidylethanolamine; and (d) biogenesis of lipid droplets, with increased size and numbers. Moreover, we detected increased mitochondrial superoxide species production in fibroblasts and mitochondrial respiration impairment in patient muscle biopsy tissues. Our findings shed light on the pathophysiology of HLD18 and broaden our understanding of the role of sphingolipid metabolism in MAM function.
- 8 July 2021
- Published by Wiley in Neuropathology and Applied Neurobiology
- Vol. 48 (1)
Modulation of mitochondrial and inflammatory homeostasis through RIP140 is neuroprotective in an adrenoleukodystrophy mouse model
Aims: Mitochondrial dysfunction and inflammation are at the core of axonal degeneration in several multifactorial neurodegenerative diseases, including multiple sclerosis, Alzheimer's disease, and Parkinson's disease. The transcriptional coregulator RIP140/NRIP1 (receptor‐interacting protein 140) modulates these functions in liver and adipose tissue, but its role in the nervous system remains unexplored. Here, we investigated the impact of RIP140 in the Abcd1− mouse model of X‐linked adrenoleukodystrophy (X‐ALD), a genetic model of chronic axonopathy involving the convergence of redox imbalance, bioenergetic failure, and chronic inflammation.Methods and results: We provide evidence that RIP140 is modulated through a redox‐dependent mechanism driven by very long‐chain fatty acids (VLCFAs), the levels of which are increased in X‐ALD. Genetic inactivation of RIP140 prevented mitochondrial depletion and dysfunction, bioenergetic failure, inflammatory dysregulation, axonal degeneration and associated locomotor disabilities in vivo in X‐ALD mouse models.Conclusions: Together, these findings show that aberrant overactivation of RIP140 promotes neurodegeneration in X‐ALD, underscoring its potential as a therapeutic target for X‐ALD and other neurodegenerative disorders that present with metabolic and inflammatory dyshomeostasis.
- 8 July 2021
- Published by Wiley in Neuropathology and Applied Neurobiology
- Vol. 48 (1)
Modulation of mitochondrial and inflammatory homeostasis through RIP140 is neuroprotective in an adrenoleukodystrophy mouse model
Aims: Mitochondrial dysfunction and inflammation are at the core of axonal degeneration in several multifactorial neurodegenerative diseases, including multiple sclerosis, Alzheimer's disease, and Parkinson's disease. The transcriptional coregulator RIP140/NRIP1 (receptor‐interacting protein 140) modulates these functions in liver and adipose tissue, but its role in the nervous system remains unexplored. Here, we investigated the impact of RIP140 in the Abcd1− mouse model of X‐linked adrenoleukodystrophy (X‐ALD), a genetic model of chronic axonopathy involving the convergence of redox imbalance, bioenergetic failure, and chronic inflammation.Methods and results: We provide evidence that RIP140 is modulated through a redox‐dependent mechanism driven by very long‐chain fatty acids (VLCFAs), the levels of which are increased in X‐ALD. Genetic inactivation of RIP140 prevented mitochondrial depletion and dysfunction, bioenergetic failure, inflammatory dysregulation, axonal degeneration and associated locomotor disabilities in vivo in X‐ALD mouse models.Conclusions: Together, these findings show that aberrant overactivation of RIP140 promotes neurodegeneration in X‐ALD, underscoring its potential as a therapeutic target for X‐ALD and other neurodegenerative disorders that present with metabolic and inflammatory dyshomeostasis.
- Open Access
- 15 August 2020
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 7 (9) , 1574-1579
A novel hypomorphic splice variant in EIF2B5 gene is associated with mild ovarioleukodystrophy
Objective: To identify the genetic cause in an adult ovarioleukodystrophy patient resistant to diagnosis.Methods: We applied whole‐exome sequencing (WES) to a vanishing white matter disease patient associated with premature ovarian failure at 26 years of age. We functionally tested an intronic variant by RT‐PCR on patient’s peripheral blood mononuclear cells (PBMC) and by minigene splicing assay.Results: WES analysis identified two novel variants in the EIF2B5 gene: c.725A > G (p.Tyr242Cys) and an intronic noncanonical mutation (c.1156 + 13G>A). This intronic mutation resulted into generation of various isoforms both in patient’s PBMC and in the minigene splicing assay, showing that ~20% residual wild‐type isoform is still expressed by the intronic‐mutated allele alone, concordant with an hypomorphic effect of this variant.Conclusion: We report two novel variants in EIF2B5, one of them a noncanonical intronic splice variant, located at a +13 intronic position. This position is mutated only in 0.05% of ClinVar intronic mutations described so far. Furthermore, we illustrate how minigene splicing assay may be advantageous when validating splice‐altering variants, in this case highlighting the coexistence of wild‐type and mutated forms, probably explaining this patient’s milder, late‐onset phenotype.
- 15 August 2020
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 7 (9) , 1574-1579
Open AccessA novel hypomorphic splice variant in EIF2B5 gene is associated with mild ovarioleukodystrophy
Objective: To identify the genetic cause in an adult ovarioleukodystrophy patient resistant to diagnosis.Methods: We applied whole‐exome sequencing (WES) to a vanishing white matter disease patient associated with premature ovarian failure at 26 years of age. We functionally tested an intronic variant by RT‐PCR on patient’s peripheral blood mononuclear cells (PBMC) and by minigene splicing assay.Results: WES analysis identified two novel variants in the EIF2B5 gene: c.725A > G (p.Tyr242Cys) and an intronic noncanonical mutation (c.1156 + 13G>A). This intronic mutation resulted into generation of various isoforms both in patient’s PBMC and in the minigene splicing assay, showing that ~20% residual wild‐type isoform is still expressed by the intronic‐mutated allele alone, concordant with an hypomorphic effect of this variant.Conclusion: We report two novel variants in EIF2B5, one of them a noncanonical intronic splice variant, located at a +13 intronic position. This position is mutated only in 0.05% of ClinVar intronic mutations described so far. Furthermore, we illustrate how minigene splicing assay may be advantageous when validating splice‐altering variants, in this case highlighting the coexistence of wild‐type and mutated forms, probably explaining this patient’s milder, late‐onset phenotype.
- 8 June 2020
- Published by Wiley in Brain Pathology
- Vol. 30 (5) , 945-963
High‐dose biotin restores redox balance, energy and lipid homeostasis, and axonal health in a model of adrenoleukodystrophy
Biotin is an essential cofactor for carboxylases that regulates the energy metabolism. Recently, high‐dose pharmaceutical‐grade biotin (MD1003) was shown to improve clinical parameters in a subset of patients with chronic progressive multiple sclerosis. To gain insight into the mechanisms of action, we investigated the efficacy of high‐dose biotin in a genetic model of chronic axonopathy caused by oxidative damage and bioenergetic failure, the Abcd1− mouse model of adrenomyeloneuropathy. High‐dose biotin restored redox homeostasis driven by NRF‐2, mitochondria biogenesis and ATP levels, and reversed axonal demise and locomotor impairment. Moreover, we uncovered a concerted dysregulation of the transcriptional program for lipid synthesis and degradation in the spinal cord likely driven by aberrant SREBP‐1c/mTORC1signaling. This resulted in increased triglyceride levels and lipid droplets in motor neurons. High‐dose biotin normalized the hyperactivation of mTORC1, thus restoring lipid homeostasis. These results shed light into the mechanism of action of high‐dose biotin of relevance for neurodegenerative and metabolic disorders.
- 8 June 2020
- Published by Wiley in Brain Pathology
- Vol. 30 (5) , 945-963
High‐dose biotin restores redox balance, energy and lipid homeostasis, and axonal health in a model of adrenoleukodystrophy
Biotin is an essential cofactor for carboxylases that regulates the energy metabolism. Recently, high‐dose pharmaceutical‐grade biotin (MD1003) was shown to improve clinical parameters in a subset of patients with chronic progressive multiple sclerosis. To gain insight into the mechanisms of action, we investigated the efficacy of high‐dose biotin in a genetic model of chronic axonopathy caused by oxidative damage and bioenergetic failure, the Abcd1− mouse model of adrenomyeloneuropathy. High‐dose biotin restored redox homeostasis driven by NRF‐2, mitochondria biogenesis and ATP levels, and reversed axonal demise and locomotor impairment. Moreover, we uncovered a concerted dysregulation of the transcriptional program for lipid synthesis and degradation in the spinal cord likely driven by aberrant SREBP‐1c/mTORC1signaling. This resulted in increased triglyceride levels and lipid droplets in motor neurons. High‐dose biotin normalized the hyperactivation of mTORC1, thus restoring lipid homeostasis. These results shed light into the mechanism of action of high‐dose biotin of relevance for neurodegenerative and metabolic disorders.
- 9 April 2019
- Published by Wolters Kluwer Health in Neurology
- Vol. 92 (15_supplem)
Beneficial Effects of High-dose Biotin (MD1003) in Models of X-linked adrenoleukodystrophy (P1.2-084)
- 9 April 2019
- Published by Wolters Kluwer Health in Neurology
- Vol. 92 (15_supplem)
Beneficial Effects of High-dose Biotin (MD1003) in Models of X-linked adrenoleukodystrophy (P1.2-084)
- 28 January 2019
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 129 (3) , 1240-1256
Loss of the sphingolipid desaturase DEGS1 causes hypomyelinating leukodystrophy
Sphingolipid imbalance is the culprit in a variety of neurological diseases, some affecting the myelin sheath. We have used whole exome sequencing in patients with undetermined leukoencephalopathies to uncover the endoplasmic reticulum lipid desaturase DEGS1 as the causative gene in nineteen patients from thirteen unrelated families. Shared features among the cases include severe motor arrest, early nystagmus, dystonia, spasticity and profound failure to thrive. MRI showed hypomyelination, thinning of corpus callosum and progressive thalami and cerebellar atrophy, suggesting a critical role of DEGS1 in myelin development and maintenance. This enzyme converts dihydroceramide (DhCer) into ceramide (Cer) in the final step of the de novo biosynthesis pathway. We detected a marked increase of the substrate DhCer and DhCer/Cer ratios in patient’s fibroblasts and muscle. Further, we used a knockdown approach for disease modelling in Danio rerio, followed by a preclinical test with the first-line treatment for multiple sclerosis, fingolimod (FTY720, Gilenya). The enzymatic inhibition of ceramide synthase, one step prior to DEGS1 in the pathway, by fingolimod, reduced the critical DhCer/Cer imbalance and the severe locomotor disability, increasing the number of myelinating oligodendrocytes in the zebrafish model. These proof-of-concept results pave the way to clinical translation.
- 28 January 2019
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 129 (3) , 1240-1256
Loss of the sphingolipid desaturase DEGS1 causes hypomyelinating leukodystrophy
Sphingolipid imbalance is the culprit in a variety of neurological diseases, some affecting the myelin sheath. We have used whole exome sequencing in patients with undetermined leukoencephalopathies to uncover the endoplasmic reticulum lipid desaturase DEGS1 as the causative gene in nineteen patients from thirteen unrelated families. Shared features among the cases include severe motor arrest, early nystagmus, dystonia, spasticity and profound failure to thrive. MRI showed hypomyelination, thinning of corpus callosum and progressive thalami and cerebellar atrophy, suggesting a critical role of DEGS1 in myelin development and maintenance. This enzyme converts dihydroceramide (DhCer) into ceramide (Cer) in the final step of the de novo biosynthesis pathway. We detected a marked increase of the substrate DhCer and DhCer/Cer ratios in patient’s fibroblasts and muscle. Further, we used a knockdown approach for disease modelling in Danio rerio, followed by a preclinical test with the first-line treatment for multiple sclerosis, fingolimod (FTY720, Gilenya). The enzymatic inhibition of ceramide synthase, one step prior to DEGS1 in the pathway, by fingolimod, reduced the critical DhCer/Cer imbalance and the severe locomotor disability, increasing the number of myelinating oligodendrocytes in the zebrafish model. These proof-of-concept results pave the way to clinical translation.
- Open Access
- 11 July 2018
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 10 (8) , e8604
Aberrant regulation of the GSK‐3β/NRF2 axis unveils a novel therapy for adrenoleukodystrophy
The nuclear factor erythroid 2‐like 2 (NRF2) is the master regulator of endogenous antioxidant responses. Oxidative damage is a shared and early‐appearing feature in X‐linked adrenoleukodystrophy (X‐ALD) patients and the mouse model (Abcd1 null mouse). This rare neurometabolic disease is caused by the loss of function of the peroxisomal transporter ABCD1, leading to an accumulation of very long‐chain fatty acids and the induction of reactive oxygen species of mitochondrial origin. Here, we identify an impaired NRF2 response caused by aberrant activity of GSK‐3β. We find that GSK‐3β inhibitors can significantly reactivate the blunted NRF2 response in patients’ fibroblasts. In the mouse models (Abcd1− and Abcd1−/Abcd2−/− mice), oral administration of dimethyl fumarate (DMF/BG12/Tecfidera), an NRF2 activator in use for multiple sclerosis, normalized (i) mitochondrial depletion, (ii) bioenergetic failure, (iii) oxidative damage, and (iv) inflammation, highlighting an intricate cross‐talk governing energetic and redox homeostasis in X‐ALD. Importantly, DMF halted axonal degeneration and locomotor disability suggesting that therapies activating NRF2 hold therapeutic potential for X‐ALD and other axonopathies with impaired GSK‐3β/NRF2 axis. Synopsis This study reports an aberrant, chronic inhibition of the endogenous antioxidant response driven by NRF2 in adrenoleukodystrophy. Reactivating this pathway in the mouse model with dimethyl fumarate unveils a promising therapeutic option. NRF2‐mediated antioxidant response is impaired in X‐linked adrenoleukodystrophy (X‐ALD) mouse spinal cord and human fibroblasts. Aberrant GSK‐3β activity is responsible for the NRF2 blunted response against oxidative stress in X‐ALD fibroblasts. Molecular defects present in the X‐ALD mouse model are rescued after oral treatment with dimethyl fumarate, an NRF2 activator in current use for multiple sclerosis. Axonal degeneration and locomotor impairment in X‐ALD mouse model are prevented with dimethyl fumarate, indicating its therapeutic potential for X‐ALD patients.
- 11 July 2018
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 10 (8) , e8604
Open AccessAberrant regulation of the GSK‐3β/NRF2 axis unveils a novel therapy for adrenoleukodystrophy
The nuclear factor erythroid 2‐like 2 (NRF2) is the master regulator of endogenous antioxidant responses. Oxidative damage is a shared and early‐appearing feature in X‐linked adrenoleukodystrophy (X‐ALD) patients and the mouse model (Abcd1 null mouse). This rare neurometabolic disease is caused by the loss of function of the peroxisomal transporter ABCD1, leading to an accumulation of very long‐chain fatty acids and the induction of reactive oxygen species of mitochondrial origin. Here, we identify an impaired NRF2 response caused by aberrant activity of GSK‐3β. We find that GSK‐3β inhibitors can significantly reactivate the blunted NRF2 response in patients’ fibroblasts. In the mouse models (Abcd1− and Abcd1−/Abcd2−/− mice), oral administration of dimethyl fumarate (DMF/BG12/Tecfidera), an NRF2 activator in use for multiple sclerosis, normalized (i) mitochondrial depletion, (ii) bioenergetic failure, (iii) oxidative damage, and (iv) inflammation, highlighting an intricate cross‐talk governing energetic and redox homeostasis in X‐ALD. Importantly, DMF halted axonal degeneration and locomotor disability suggesting that therapies activating NRF2 hold therapeutic potential for X‐ALD and other axonopathies with impaired GSK‐3β/NRF2 axis. Synopsis This study reports an aberrant, chronic inhibition of the endogenous antioxidant response driven by NRF2 in adrenoleukodystrophy. Reactivating this pathway in the mouse model with dimethyl fumarate unveils a promising therapeutic option. NRF2‐mediated antioxidant response is impaired in X‐linked adrenoleukodystrophy (X‐ALD) mouse spinal cord and human fibroblasts. Aberrant GSK‐3β activity is responsible for the NRF2 blunted response against oxidative stress in X‐ALD fibroblasts. Molecular defects present in the X‐ALD mouse model are rescued after oral treatment with dimethyl fumarate, an NRF2 activator in current use for multiple sclerosis. Axonal degeneration and locomotor impairment in X‐ALD mouse model are prevented with dimethyl fumarate, indicating its therapeutic potential for X‐ALD patients.
- Open Access
- 1 May 2018
- Published by Elsevier in Cell Reports
- Vol. 23 (6) , 1665-1677
Inhibition of Gsk3b Reduces Nfkb1 Signaling and Rescues Synaptic Activity to Improve the Rett Syndrome Phenotype in Mecp2-Knockout Mice
- 1 May 2018
- Published by Elsevier in Cell Reports
- Vol. 23 (6) , 1665-1677
Open AccessInhibition of Gsk3b Reduces Nfkb1 Signaling and Rescues Synaptic Activity to Improve the Rett Syndrome Phenotype in Mecp2-Knockout Mice
- Open Access
- 3 March 2018
- Published by Impact Journals, LLC in Aging
- Vol. 10 (3) , 295-296
SIRT2 in age-related neurodegenerative disorders
- 3 March 2018
- Published by Impact Journals, LLC in Aging
- Vol. 10 (3) , 295-296
Open AccessSIRT2 in age-related neurodegenerative disorders